Repurposing Thioridazine (TDZ) as an anti-inflammatory agent

Mirza S. Baig, Anjali Roy, Uzma Saqib, Sajjan Rajpoot, Mansi Srivastava, Adnan Naim, Dongfang Liu, Rohit Saluja, Syed M. Faisal, Qiuwei Pan, Kati Turkowski, Gajanan N. Darwhekar, Rajkumar Savai

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Nuclear factor-kB (NF-kB) is a crucial transcription factor in the signal transduction cascade of the inflammatory signaling. Activation of NF-κB depends on the phosphorylation of IκBα by IκB kinase (IKKβ) followed by subsequent ubiquitination and degradation. This leads to the nuclear translocation of the p50- p65 subunits of NF-κB, and further triggers pro-inflammatory cytokine gene expression. Thus, in the need of a more effective therapy for the treatment of inflammatory diseases, specific inhibition of IKKβ represents a rational alternative strategy to the current therapies. A computer-aided drug identification protocol was followed to identify novel IKKβ inhibitors from a database of over 1500 Food and Drug Administration (FDA) drugs. The best scoring compounds were compared with the already known high-potency IKKβ inhibitors for their ability to bind and inhibit IKKβ by evaluating their docking energy. Finally, Thioridazinehydrochloride (TDZ), a potent antipsychotic drug against Schizophrenia was selected and its efficiency in inhibiting IκBα protein degradation and NF-κB activation was experimentally validated. Our study has demonstrated that TDZ blocks IκBα protein degradation and subsequent NF-κB activation to inhibit inflammation. Thus, it is a potential repurposed drug against inflammation.

Original languageEnglish (US)
Article number12471
JournalScientific Reports
Issue number1
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Repurposing Thioridazine (TDZ) as an anti-inflammatory agent'. Together they form a unique fingerprint.

Cite this